$1.41
1.44% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
IL0010852080
Symbol
CGEN
Sector
Industry

Compugen Ltd. Stock price

$1.41
+0.02 1.44% 1M
-0.02 1.40% 6M
-0.12 7.84% YTD
-0.33 18.97% 1Y
-0.46 24.60% 3Y
-13.05 90.25% 5Y
-5.01 78.04% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.02 1.44%
ISIN
IL0010852080
Symbol
CGEN
Sector
Industry

Key metrics

Market capitalization $131.85m
Enterprise Value $30.87m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 1.12
P/S ratio (TTM) P/S ratio 4.78
P/B ratio (TTM) P/B ratio 2.31
Revenue growth (TTM) Revenue growth -23.40%
Revenue (TTM) Revenue $27.59m
EBIT (operating result TTM) EBIT $-14.79m
Cash position $103.75m
EPS (TTM) EPS $-0.16
P/E forward negative
P/S forward 9.29
EV/Sales forward 2.18
Short interest 1.90%
Show more

Is Compugen Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Compugen Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Compugen Ltd. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Compugen Ltd. forecast:

Buy
100%

Financial data from Compugen Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
28 28
23% 23%
100%
- Direct Costs 8.23 8.23
100% 100%
30%
19 19
39% 39%
70%
- Selling and Administrative Expenses 9.98 9.98
2% 2%
36%
- Research and Development Expense 24 24
28% 28%
88%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
30% 30%
-54%
Net Profit -14 -14
15% 15%
-51%

In millions USD.

Don't miss a Thing! We will send you all news about Compugen Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Compugen Ltd. Stock News

Neutral
Seeking Alpha
one day ago
Compugen Ltd. (NASDAQ:CGEN ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR & Corporate Communications Anat Cohen-Dayag - President & CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Daina Graybosch - Leerink Partners Rohan Mathur - Oppenheimer Asth...
Neutral
PRNewsWire
one day ago
Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025 Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to Gilead Partner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung, gastrointestinal and endometrial ...
Neutral
PRNewsWire
8 days ago
Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of Directors Eran Ophir, Ph.D.
More Compugen Ltd. News

Company Profile

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Head office Israel
CEO Anat Cohen-Dayag
Employees 74
Founded 1993
Website www.cgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today